Insider Selling: Axon Enterprise (NASDAQ:AXON) Insider Sells $800,000.00 in Stock

Axon Enterprise, Inc (NASDAQ:AXONGet Free Report) insider Isaiah Fields sold 2,000 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $400.00, for a total value of $800,000.00. Following the sale, the insider owned 52,813 shares in the company, valued at $21,125,200. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Isaiah Fields also recently made the following trade(s):

  • On Friday, February 27th, Isaiah Fields sold 2,000 shares of Axon Enterprise stock. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00.

Axon Enterprise Trading Up 12.3%

Shares of AXON stock opened at $439.32 on Friday. The firm has a market cap of $35.41 billion, a P/E ratio of 176.43, a PEG ratio of 7.11 and a beta of 1.44. Axon Enterprise, Inc has a 1-year low of $339.01 and a 1-year high of $885.91. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.27 and a quick ratio of 1.93. The firm’s 50-day simple moving average is $408.72 and its 200-day simple moving average is $494.98.

Axon Enterprise (NASDAQ:AXONGet Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.01. The business had revenue of $807.35 million for the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.78%. The company’s revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.47 EPS. As a group, equities analysts forecast that Axon Enterprise, Inc will post 1.82 EPS for the current year.

Institutional Trading of Axon Enterprise

Hedge funds have recently made changes to their positions in the company. Evergreen Capital Management LLC lifted its holdings in Axon Enterprise by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 15 shares during the last quarter. Monte Financial Group LLC lifted its holdings in Axon Enterprise by 5.5% during the 3rd quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after purchasing an additional 17 shares during the last quarter. Wealth Alliance LLC lifted its holdings in Axon Enterprise by 3.2% during the 3rd quarter. Wealth Alliance LLC now owns 583 shares of the biotechnology company’s stock valued at $419,000 after purchasing an additional 18 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Axon Enterprise by 1.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,631 shares of the biotechnology company’s stock valued at $1,350,000 after purchasing an additional 19 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI lifted its holdings in Axon Enterprise by 4.5% during the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 439 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 19 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Craig Hallum reiterated a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a report on Wednesday, February 25th. Barclays cut their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Zacks Research upgraded shares of Axon Enterprise from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Piper Sandler cut their price target on shares of Axon Enterprise from $690.00 to $674.00 and set an “overweight” rating on the stock in a report on Thursday, May 7th. Finally, Citizens Jmp cut their price target on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $712.75.

Read Our Latest Stock Analysis on AXON

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

About Axon Enterprise

(Get Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.

Further Reading

Insider Buying and Selling by Quarter for Axon Enterprise (NASDAQ:AXON)

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.